neuropathic pain market and - pharma intelligence/media/in... · pharma intelligence | informa...
TRANSCRIPT
YEAR US JAPAN FRANCE GERMANY ITALY SPAIN UKGRANDTOTAL
2017201820192020202120222023202420252026
7,6198,0245,7385,5665,6395,7855,9655,9806,1396,133
404395388382375364350339329319
45434241404040404041
199185182178176174174175179188
70696969707071727372
52535455555556575958
130132134136138140142144147152
8,5198,9016,6076,4276,4926,6286,7976,8076,9656,962
Datamonitor Healthcare Pharma intelligence | informa
Report Store Pharma intelligence | informa
Datamonitor Healthcare estimates the neuropathic pain market to total $8.5bn in 2017 across the US, Japan, and five major EU markets (France, Germany, Italy, Spain, and the UK).
Neuropathic pain sales will decline at a CAGR of -2.2% over 2017–26, peaking at $8.9bn in 2018 before contracting due to Lyrica’s patent cliff.
The primary driver of initial market growth relies on continued uptake of gold-standard Lyrica, as effective alternatives remain few and far between.
Neuropathic Pain Market and Forecast Analysis to 2026
Neuropathic pain drug sales acrossthe US, Japan, and five major EUmarkets, by country ($m), 2017-26
NOTICE: TOTALS MAY NOT SUM
DUE TO ROUNDING
ANTI-CONVULSANTS
ANTI-DEPRESSANTS ANXIOLYTICS
GENE THERAPIES OPOIDS
OTHER ORALGESTICS
GRANDTOTAL
2017201820192020202120222023202420252026
729713741750758766775784794803
4,4534,7002,2931,9881,8961,8371,7931,5821,5241,552
344346352357363370377385393401
2222222222
---338101176263363458
2,8492,9723,0633,1643,2663,3763,4913,6013,6933,543
142149156163169176183190197204
8,5198,9016,6076,4276,4926,6286,7976,8076,9656,962
ANESTHETICSYEAR
Drug sales across the US, Japan, and five major EU markets, by DRUG CLASS ($m), 2017-26
CompanyNovartis
Aeterna
GET THE FULL REPORT
HERE
CLICK HERE
“With Lyrica’s patent cliff, Datamonitor Healthcare estimates that neuropathic pain sales will fall from $8.52bn in 2017 to $6.96bn in 2026” CLICK TO TWEET THIS!
The full 290-page report includes an assessment of:
• Key neuropathic pain therapies on the market and in the late-phase pipeline
• Neuropathic pain market dynamics
• A 10-year patient-based sales forecast.
20% discount
pain20
use the code below to get your discount